URGN · UroGen Pharma Ltd.
$40.63
+0.18 (+0.44%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$2.02B
Shares
48.88M
Volume · Sep 30
641.38K
Avg daily vol (3M)
837.83K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$40.63
Open$40.72
Day$40.09–41.10
52W close$16.42–50.29
Avg vol 30d795K
Short int6.2M · 12.8% float · 9.2d
Short vol79%
Last earningsAug 5, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 5 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$188.73M
Trailing 12 months
Net income (TTM)
−$97.64M
Trailing 12 months
Revenue growth YoY
+199.2%
Year over year
Operating margin
-35.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-7.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$79.44M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.5%
Year over year · more shares
Price change (1Y)
+111.3%
Trailing year
Short interest
12.8%
Latest settlement · 9.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+37%
above
Price vs 50-day avg
−7%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
71%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−6%
trailing
6-month return
+98%
trailing
YTD return
+73%
this year
Relative strength
+86%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $44 › 200d $30 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +39 funds added
Insider flow
Distributing
Net -$3.0M over 90 days · 100% sells
Short interest
Rising
12.78% of float · ▲ +0.0% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
191 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
−86%
Y/Y
Gross margin
8630%
expanding
Free cash flow
$-162.7M
Balance sheet
$14.3M
net debt
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
2026 net product revenue for JELMYTO
· full-year 2026
Initiated
$97M – $101M
Full-year 2026 operating expenses
· full-year 2026
Initiated
$260M – $270M
Guided vs delivered
· last 1 settled
Full year 2021 revenue
full year 2021
guided $47M – $51M
$48.04M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+37%
Bullish
Price vs 50-day avg
−7%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
71%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $44 › 200d $30 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +39 funds added
Insider flow
Distributing
Net -$3.0M over 90 days · 100% sells
Short interest
Rising
12.78% of float · ▲ +0.0% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
191 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $16
Now $41 · 71%
Range high $50
vs 200-day avg +37%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
URGN
this stock
UroGen Pharma Ltd.
|
$2.02B | +73.5% | -86.2% | — | 12.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| URGN | -2.4% | -6.4% | +97.9% | -5.7% | +73.5% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -1.7% | -6.5% | +85.7% | -5.1% | +61.6% |